Targeted Immunomodulation Transforms Dermatomyositis Management: Phase 3 Brepocitinib Trial Demonstrates Significant Clinical Benefits
Researchers have demonstrated substantial therapeutic benefits for brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, in adults with dermatomyositis, according to findings from a Phase 3 clinical trial published…
Continue Reading
Targeted Immunomodulation Transforms Dermatomyositis Management: Phase 3 Brepocitinib Trial Demonstrates Significant Clinical Benefits
